MCK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
["Not a good buy right now: price is aggressively extended after an earnings/guidance-driven surge (+15.25% regular session, +4.87% pre-market previously), with RSI(6)=82.87 (overbought) and price pushing into the upper resistance zone.", "Upside looks near-term capped vs Street targets: current ~$947 is already close to key targets (MS $966, Barclays $960), leaving limited immediate room before hitting heavy resistance (R2 ~967).", "Intellectia Proprietary Trading Signals\n- AI Stock Picker: no signal on given stock today.\n- SwingMax: No signal on given stock recently.", "If you must act immediately (impatient entry), this is higher-risk timing; the better risk/reward would typically come on a pullback toward the ~931 pivot/R1 area or below\u2014but based on your requirement to act now, the best call is HOLD rather than chase."]
["Trend: Strong bullish trend (SMA_5 > SMA_20 > SMA_200) with momentum accelerating; MACD histogram +8.581 and expanding confirms upside momentum.", "Overbought/extension: RSI_6 at 82.87 signals near-term exhaustion risk (common after earnings gaps).", "Key levels: Pivot 872.65; R1 931.04 (now below price, likely first support on pullbacks); R2 967.11 (major nearby resistance).", "Market context: S&P 500 down ~1.01% while MCK surged\u2014relative strength is excellent but also suggests a crowded/extended move that can mean mean-reversion risk."]
["Earnings beat + guidance raise: Q3 revenue $106.2B (+11% YoY) and raised FY2026 EPS guidance; Q3 non-GAAP EPS beat expectations (reported around ~$9.34 non-GAAP; snapshot EPS $9.59).", "Fundamental momentum: Net income +34.93% YoY and EPS +38.18% YoY in 2026/Q3 supports continuation of the uptrend.", "Policy/industry tailwind narrative: Morgan Stanley cites a \u201cGolden Era\u201d for healthcare distribution and relative policy insulation.", "Congress trading: last 90 days shows 4 purchases and 0 sales (median ~$0.8M), signaling positive sentiment among influential buyers."]
and extended after a sharp gap\u2014probability of near-term pullback/consolidation is elevated.", "Resistance overhead: R2 ~967 is close; multiple analyst targets cluster around $960\u2013$966, which can act like an anchor/resistance zone.", "High implied volatility: IV percentile ~94 suggests elevated premium and potential for post-event volatility crush / choppy trading (even if the long-term story is intact).", "Strategic transaction risk: Planned exit/separation of med-surgical business is viewed as likely dilutive (per Deutsche Bank), adding complexity to the forward setup."]
["Latest quarter: 2026/Q3.", "Revenue: $106.158B, +11.40% YoY (strong top-line growth for a distributor at this scale).", "Profitability: Net income $1.186B, +34.93% YoY; EPS +38.18% YoY to 9.59\u2014growth is accelerating faster than revenue.", "Margins: Gross margin 3.47, +1.76% YoY (modest but positive improvement, important in a low-margin distribution model)."]
["Recent trend: Mostly price target raises/positive initiations, indicating improving Street confidence after results and outlook.", "Morgan Stanley (2026-01-29): Overweight; PT raised to $966 from $916 (bullish, sees multiple expansion potential).", "Barclays (2025-12-08): Initiated Overweight; PT $960 (bullish on drug distributors).", "Deutsche Bank (2025-12-10): Buy; PT raised to $904 from $861; notes med-surg separation could be dilutive but stock can still perform.", "Wells Fargo (2025-11-10): Equal Weight; PT raised to $914 from $816 (more neutral stance despite model upgrades).", "Mizuho (2025-11-07): Neutral; PT raised to $880 from $770 (neutral but improving expectations).", "Wall Street pros/cons view: Pros\u2014durable distribution tailwinds, earnings momentum, perceived policy insulation. Cons\u2014transaction/separation complexity and, at today\u2019s price, upside to many targets looks limited near-term."]
